IGA NEPHROPATHY (IGAN)
Clinical trials for IGA NEPHROPATHY (IGAN) explained in plain language.
Never miss a new study
Get alerted when new IGA NEPHROPATHY (IGAN) trials appear
Sign up with your email to follow new studies for IGA NEPHROPATHY (IGAN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Herbal granules aim to reduce kidney damage in IgA patients
Disease control Not yet recruitingThis study tests whether Shenqi Yishen Granules, a traditional Chinese medicine, can lower protein levels in the urine of adults with IgA nephropathy, a kidney disease. About 102 participants will receive either the granules or a placebo to compare effects. The trial focuses on k…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: NA • Sponsor: Keda Lu • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
Engineered immune cells take on tough kidney diseases in first human test
Disease control Not yet recruitingThis early-phase study tests a new treatment for people with autoimmune kidney diseases (lupus nephritis, IgA nephropathy, or membranous nephropathy) that have not responded to standard therapies. The treatment uses specially engineered immune cells (CAR-γδ T cells) designed to t…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: EARLY_PHASE1 • Sponsor: Air Force Military Medical University, China • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
New cell injection aims to tame kidney disease
Disease control Not yet recruitingThis early-stage trial tests a new cell therapy called GT719 in about 30 adults with kidney diseases caused by the immune system, such as IgA nephropathy and membranous nephropathy. The main goals are to check if the treatment is safe and to find the best dose. Researchers will a…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
New drug tested in kidney patients – early safety check
Knowledge-focused Not yet recruitingThis early-phase study tests an experimental drug called RG002C0106 in 24 adults to see how kidney function affects its safety and how the body processes it. Participants include people with normal kidneys and those with mild-to-moderate kidney impairment, including IgA nephropat…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: PHASE1 • Sponsor: Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. • Aim: Knowledge-focused
Last updated Apr 30, 2026 15:50 UTC